Interstitial lung disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:02:57 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Interstitial lung disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/efficacy-and-safety-of-subcutaneous-belimumab-in-adults-with-connective-tissue-disease-associated-interstitial-lung-disease/ Tue, 02 Jun 2026 04:16:37 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-of-subcutaneous-belimumab-in-adults-with-connective-tissue-disease-associated-interstitial-lung-disease/ This clinical trial is focused on studying a group of lung conditions known as Interstitial Lung Disease (ILD), which are associated with Connective Tissue Disease (CTD). These diseases can cause scarring of the lungs, leading to breathing difficulties. The study will evaluate the effectiveness and safety of a medication called Belimumab, which is given as an injection under the skin. Belimumab is being tested to see if it can help reduce the decline in lung function in people with ILD related to CTD.

The trial will compare the effects of Belimumab to a placebo, in addition to the standard treatments that participants are already receiving for their condition. Participants will receive either Belimumab or a placebo through injections over a period of 52 weeks. The main goal is to see if Belimumab can help maintain lung volume better than the placebo. Throughout the study, participants will be monitored for changes in their lung function and overall health.

Participants in the study will be adults who have been diagnosed with ILD associated with CTD, such as Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), or other similar conditions. The study aims to provide more information on whether Belimumab can be a beneficial addition to the current treatment options for these lung diseases. The trial will also track any side effects or health changes experienced by participants during the study period.

]]> Carboplatin‑based drug combination for advanced non‑small cell lung cancer patients with interstitial lung disease https://clinicaltrials.eu/trial/carboplatin-based-drug-combination-for-advanced-non-small-cell-lung-cancer-patients-with-interstitial-lung-disease/ Wed, 29 Apr 2026 15:09:58 +0000 https://clinicaltrials.eu/trial/carboplatin-based-drug-combination-for-advanced-non-small-cell-lung-cancer-patients-with-interstitial-lung-disease/ The trial focuses on people with advanced Non Small Cell Lung Cancer who also have Interstitial Lung Disease. In the first treatment stage, the chemotherapy drugs carboplatin and paclitaxel are given, sometimes together with the targeted drug bevacizumab. In the second stage, patients may receive another chemotherapy chosen by the doctor or one of the immune‑based medicines pembrolizumab or nivolumab.

The main goal is to see how well the first set of medicines controls the cancer and to assess how the second‑line medicines affect breathing problems caused by the lung disease. Participants receive a series of intravenous infusions over several weeks, followed by regular check‑ups that include blood tests and imaging. Imaging is performed with a CT scan, which is a special X‑ray that creates detailed pictures of the lungs and chest.

After the initial treatment period, patients are monitored for up to six months to record any worsening of breathing that might require stopping the medication, as well as overall health outcomes such as how long the disease stays stable and overall survival. All side effects are recorded and graded according to standard cancer‑treatment safety guidelines. The study follows a set schedule of clinic visits, drug administration, and imaging assessments.

]]> A study to evaluate the safety and effectiveness of inhaled treprostinil in patients with pulmonary hypertension associated with interstitial lung disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-inhaled-treprostinil-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ Wed, 29 Apr 2026 15:09:25 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-safety-and-effectiveness-of-inhaled-treprostinil-in-patients-with-pulmonary-hypertension-associated-with-interstitial-lung-disease/ This study is being conducted to evaluate the safety and effectiveness of a new inhaled medication called L606, which contains treprostinil liposome, for people living with Pulmonary Hypertension associated with Interstitial Lung Disease. This condition is a type of high blood pressure in the lungs that occurs in individuals who also have scarring or inflammation of the lung tissue. The treatment is delivered through inhalation, which means the medication is breathed in through the lungs.

Participants in the study will be assigned to receive either L606 or a placebo. This research involves a randomized and double-blind process, meaning that neither the participants nor the researchers know which specific treatment is being administered until the study is finished. The study will monitor how the medication affects the ability to walk and other health factors over a period of time.

]]> Using 68Ga-FAPI-46 imaging to detect fibrosis in patients with inflammatory diseases such as Crohn’s disease, ulcerative colitis, systemic sclerosis, and lung fibrosis. https://clinicaltrials.eu/trial/using-68ga-fapi-46-imaging-to-detect-fibrosis-in-patients-with-inflammatory-diseases-such-as-crohn-s-disease-ulcerative-colitis-systemic-sclerosis-and-lung-fibrosis/ Wed, 29 Apr 2026 15:09:16 +0000 https://clinicaltrials.eu/trial/using-68ga-fapi-46-imaging-to-detect-fibrosis-in-patients-with-inflammatory-diseases-such-as-crohn-s-disease-ulcerative-colitis-systemic-sclerosis-and-lung-fibrosis/ This study focuses on several conditions involving fibrosis, which is the development of excess scar tissue in the body. The diseases being studied include Idiopathic inflammatory myopathy, Crohn’s disease, Ulcerative colitis, Fibrotic hypersensitivity pneumonitis, Idiopathic pulmonary fibrosis, Unclassifiable interstitial lung disease, and Systemic sclerosis. These conditions are often part of a group known as immune-mediated inflammatory diseases, where the body’s immune system causes inflammation that can lead to organ damage.

The purpose of the study is to evaluate the use of 68Ga-FAPI-46 to detect scar tissue inside the body. This substance is a radiopharmaceutical, which is a specialized drug used for medical imaging. Participants will undergo a PET/CT scan, a method that combines two types of imaging to create detailed pictures of the body’s internal structures. During the process, the substance is administered through an intravenous injection, meaning it is delivered directly into a vein.

Throughout the study, the imaging results will be compared with biological samples to see how well the scan identifies certain markers of scarring. Researchers will also look at how the substance moves through the body and how it can be used to better understand the progression of these diseases. This information may help in finding new ways to diagnose or treat scarring in the future.

]]> A study to evaluate the effectiveness of BI 1015550 in people with lung abnormalities and a family history of pulmonary fibrosis https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bi-1015550-in-people-with-lung-abnormalities-and-a-family-history-of-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:09:15 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-of-bi-1015550-in-people-with-lung-abnormalities-and-a-family-history-of-pulmonary-fibrosis/ This study investigates the effect of nerandomilast in reducing the risk of worsening lung abnormalities in individuals with interstitial lung diseases and a family history of pulmonary fibrosis. Pulmonary fibrosis is a condition where lung tissue becomes thick and scarred over time. The study also focuses on people with interstitial lung abnormalities, which are early signs of changes in the lungs. Familial pulmonary fibrosis refers to this lung scarring when it runs in a family.

Participants in the study will be given either nerandomilast, which is an oral medication, or a placebo. The purpose of the study is to determine if the medication can help slow down the progression of these lung changes. During the study, researchers will monitor how the lungs function and look for any changes in the lung tissue using high-resolution computed tomography, which is a detailed type of CT scan used to see the lungs more clearly.

The study is designed to last for 24 months. During this time, the effectiveness and safety of the treatment will be observed. Researchers will monitor lung function through various measures, including the amount of air the lungs can hold and how well oxygen moves from the lungs into the blood.

]]> A study to compare the effectiveness of rituximab and a placebo in patients with interstitial lung disease associated with rheumatoid arthritis https://clinicaltrials.eu/trial/a-study-to-compare-the-effectiveness-of-rituximab-and-a-placebo-in-patients-with-interstitial-lung-disease-associated-with-rheumatoid-arthritis/ Wed, 29 Apr 2026 15:09:13 +0000 https://clinicaltrials.eu/trial/a-study-to-compare-the-effectiveness-of-rituximab-and-a-placebo-in-patients-with-interstitial-lung-disease-associated-with-rheumatoid-arthritis/ This study focuses on individuals living with rheumatoid arthritis-associated interstitial lung disease, a condition where chronic inflammation from rheumatoid arthritis causes scarring and damage to the lung tissues. The purpose of this study is to determine if rituximab is more effective than a placebo in maintaining lung function. Rituximab is a medication delivered through an infusion, which is a method of administering medicine directly into a vein.

During the trial, participants will be assigned to receive either rituximab or a placebo. The study will last for 48 weeks. While receiving the assigned treatment, the progress of the lung condition and the effectiveness of the medication will be monitored to see if it helps prevent the decline of the amount of air the lungs can hold.

]]> Study of Rituximab versus Placebo to Improve Lung Function in Patients with Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) https://clinicaltrials.eu/trial/study-on-lung-function-improvement-with-rituximab-in-patients-with-granulomatous-lymphocytic-interstitial-lung-disease/ Wed, 29 Apr 2026 15:05:14 +0000 https://clinicaltrials.eu/trial/study-on-lung-function-improvement-with-rituximab-in-patients-with-granulomatous-lymphocytic-interstitial-lung-disease/ This study focuses on Granulomatous Lymphocytic Interstitial Lung Disease (GLILD), a rare lung condition that affects breathing capacity. The purpose is to evaluate how well a medication called rituximab works in improving lung function compared to placebo in people with this disease.

The treatment involves receiving rituximab or placebo through intravenous administration (delivery directly into a vein). During the study, participants will receive multiple doses of the medication or placebo over a period of about 27 weeks. The total treatment period lasts approximately 78 weeks, during which doctors will monitor changes in breathing capacity.

The medication being tested, rituximab, is already approved for use in other conditions and will be given along with sodium chloride solution, which helps deliver the medicine into the bloodstream. Throughout the study, doctors will measure how well the lungs work using various breathing tests to determine if the treatment is helping to improve lung function in people with GLILD.

]]> Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases https://clinicaltrials.eu/trial/study-to-test-if-nerandomilast-bi-1015550-helps-patients-with-interstitial-lung-disease-related-to-rheumatic-diseases/ Wed, 29 Apr 2026 15:04:11 +0000 https://clinicaltrials.eu/trial/study-to-test-if-nerandomilast-bi-1015550-helps-patients-with-interstitial-lung-disease-related-to-rheumatic-diseases/ This clinical trial is focused on studying a group of diseases known as Systemic Autoimmune Rheumatic Diseases that are associated with a lung condition called Interstitial Lung Disease (SARD-ILD). These diseases can cause inflammation and scarring in the lungs, leading to breathing difficulties. The study is testing a new treatment called nerandomilast, which is being developed to help manage lung fibrosis, a type of lung scarring, in people with these conditions.

The purpose of the study is to evaluate the effectiveness and safety of nerandomilast over a period of 26 weeks. Participants in the study will receive either the active medication, nerandomilast, or a placebo, which looks like the medication but does not contain the active ingredient. The study will monitor changes in lung health using a special type of imaging called high-resolution computed tomography (HRCT), which provides detailed pictures of the lungs. The study will also track any side effects and changes in symptoms such as cough and shortness of breath.

Participants will be involved in the study for about six months, during which they will have regular check-ups and assessments to monitor their lung condition and overall health. The study aims to provide valuable information on whether nerandomilast can improve lung function and quality of life for people with SARD-ILD. This research could lead to new treatment options for those affected by these challenging conditions.

]]> Study on the Effects of High-Flow Oxygen Therapy in Patients with Interstitial Lung Disease During Exercise https://clinicaltrials.eu/trial/study-on-the-effects-of-high-flow-oxygen-therapy-in-patients-with-interstitial-lung-disease-during-exercise/ Wed, 29 Apr 2026 15:02:34 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-high-flow-oxygen-therapy-in-patients-with-interstitial-lung-disease-during-exercise/ This clinical trial is focused on patients with Diffuse Interstitial Lung Disease (ILD), a condition that affects the lungs and can cause difficulty in breathing. The study aims to explore whether using high-flow oxygen can improve oxygen levels during exercise, which is an important part of pulmonary rehabilitation for these patients. The treatment being studied involves two types of oxygen therapy: conventional oxygen therapy using a nasal cannula and high-flow oxygen systems. The main goal is to compare how well each method helps maintain oxygen levels during muscle training exercises.

Participants in the study will undergo a series of exercises as part of their rehabilitation program. During these exercises, their oxygen levels will be monitored to see which method provides better oxygenation. The study will also look at other aspects such as how breathlessness affects daily activities and exercise capacity, as well as overall quality of life. These will be assessed using various questionnaires and tests, including the 6-minute walk test, which measures how far a person can walk in six minutes.

The study will last for a period of time, during which participants will receive either the conventional or high-flow oxygen therapy. The results will help determine if high-flow oxygen can offer additional benefits over the standard method. This information could be valuable in improving treatment strategies for patients with ILD who experience oxygen desaturation, or low oxygen levels, during physical activity.

]]> Study of Amlitelimab and BI 1015550 for Patients with Interstitial Lung Disease Due to Scleroderma https://clinicaltrials.eu/trial/study-of-amlitelimab-and-bi-1015550-for-patients-with-interstitial-lung-disease-due-to-scleroderma/ Wed, 29 Apr 2026 15:01:34 +0000 https://clinicaltrials.eu/trial/study-of-amlitelimab-and-bi-1015550-for-patients-with-interstitial-lung-disease-due-to-scleroderma/ This clinical trial is focused on studying a condition known as interstitial lung disease secondary to systemic sclerosis (SSc-ILD). This is a lung disease that occurs in people with a condition called scleroderma, which affects the skin and other organs. The study will explore the effects of two investigational treatments, Amlitelimab and BI 1015550, as well as their matching placebos. Amlitelimab is administered as a solution for injection using a pre-filled syringe, while BI 1015550 is taken orally in the form of a film-coated tablet.

The purpose of the study is to evaluate the safety and effectiveness of these investigational treatments in people with SSc-ILD. Participants will be randomly assigned to receive either the investigational treatment or a placebo. The study will last for a period of 52 weeks, during which participants will receive regular doses of the assigned treatment. Throughout the study, participants will undergo various assessments to monitor their lung function and overall health.

The main goal is to observe any changes in lung function, specifically measuring the forced vital capacity (FVC), which is the amount of air a person can exhale after taking a deep breath. This will help determine if the investigational treatments can improve lung function in people with SSc-ILD. The study will also look at other health indicators to provide a comprehensive understanding of the treatments’ effects. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and well-being.

]]> Study on Pirfenidone Inhalation Solution for Patients with Progressive Fibrosing Interstitial Lung Diseases, Including Idiopathic Pulmonary Fibrosis https://clinicaltrials.eu/trial/study-on-pirfenidone-inhalation-solution-for-patients-with-progressive-fibrosing-interstitial-lung-diseases-including-idiopathic-pulmonary-fibrosis/ Wed, 29 Apr 2026 15:00:14 +0000 https://clinicaltrials.eu/trial/study-on-pirfenidone-inhalation-solution-for-patients-with-progressive-fibrosing-interstitial-lung-diseases-including-idiopathic-pulmonary-fibrosis/ This clinical trial is focused on studying a group of lung diseases known as Interstitial Lung Diseases (ILD), which includes a specific condition called Idiopathic Pulmonary Fibrosis (IPF). These diseases cause scarring of the lung tissue, leading to breathing difficulties. The treatment being tested in this study is called Pirfenidone Solution for Inhalation, also known by its code name AP01. This medication is delivered directly to the lungs using a device called a nebulizer, which turns the solution into a mist that can be inhaled.

The purpose of the study is to allow patients to continue or start using AP01 for treating their lung conditions until it receives regulatory approval or the study ends. The study will also monitor the safety of patients while they are on this treatment. Participants in the study may include those who have previously been part of an Avalyn AP01 study or those with no other treatment options for their lung disease. The study aims to provide access to this treatment for patients who cannot use other medications like oral pirfenidone or nintedanib due to various reasons, such as intolerance or lack of availability.

Throughout the study, participants will use the Pirfenidone Solution for Inhalation as directed and will be monitored for any side effects or changes in their condition. The study will continue until the treatment is approved by regulatory authorities or until the study is concluded. The safety of the participants is a key focus, and any adverse events or issues will be carefully tracked and evaluated.

]]> Study on Senicapoc for Patients with Progressive Fibrotic Interstitial Lung Disease to Prevent Disease Progression https://clinicaltrials.eu/trial/study-on-senicapoc-for-patients-with-progressive-fibrotic-interstitial-lung-disease-to-prevent-disease-progression/ Wed, 29 Apr 2026 15:00:00 +0000 https://clinicaltrials.eu/trial/study-on-senicapoc-for-patients-with-progressive-fibrotic-interstitial-lung-disease-to-prevent-disease-progression/ This clinical trial is focused on studying the effects of a medication called Senicapoc in patients with a condition known as Progressive Fibrotic Interstitial Lung Disease (PF-ILD) or Idiopathic Pulmonary Fibrosis (IPF). These are lung diseases where the tissue in the lungs becomes scarred and stiff over time, making it difficult to breathe. The trial will compare the effects of Senicapoc to a placebo, which is a tablet that looks like the medication but does not contain any active ingredients.

The purpose of the study is to evaluate the safety and effectiveness of Senicapoc in addition to the usual care patients receive. Participants will take the medication or placebo orally in tablet form for a period of 26 weeks. During this time, researchers will monitor the rate at which the patients’ lung function declines, specifically looking at a measure called forced vital capacity (FVC), which is the amount of air a person can forcibly exhale from their lungs after taking the deepest breath possible.

Throughout the study, other aspects of the patients’ health will also be observed, such as changes in their quality of life, any hospitalizations, and any side effects they might experience. The study aims to provide valuable information on whether Senicapoc can help slow down the progression of these lung diseases and improve the overall well-being of the patients involved.

]]> Study on the Long-Term Safety of Nintedanib for Children and Adolescents with Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-nintedanib-for-children-and-adolescents-with-interstitial-lung-disease/ Wed, 29 Apr 2026 14:59:59 +0000 https://clinicaltrials.eu/trial/study-on-the-long-term-safety-of-nintedanib-for-children-and-adolescents-with-interstitial-lung-disease/ This clinical trial is focused on studying the long-term safety of a medication called nintedanib in children and adolescents who have a condition known as Childhood Interstitial Lung Disease. This disease affects the lungs, causing inflammation and scarring, which can make it difficult to breathe. The purpose of the study is to understand how safe and tolerable nintedanib is when used over a long period, alongside the usual care these patients receive.

Participants in the study will take nintedanib in the form of a soft capsule, which is taken by mouth. The study will last for at least three years, during which time researchers will monitor the participants for any side effects or adverse reactions that may occur as a result of the treatment. The study aims to gather information on how often these side effects happen and how they affect the participants.

Throughout the study, participants will continue to receive their standard medical care for Childhood Interstitial Lung Disease, and the effects of adding nintedanib to their treatment will be closely observed. The goal is to ensure that the medication is safe for long-term use in young patients and to provide valuable information that could help improve treatment options for this condition in the future.

]]> Study on BI 1015550 for Improving Lung Function in Patients with Progressive Fibrosing Interstitial Lung Diseases https://clinicaltrials.eu/trial/study-on-bi-1015550-for-improving-lung-function-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ Wed, 29 Apr 2026 14:59:20 +0000 https://clinicaltrials.eu/trial/study-on-bi-1015550-for-improving-lung-function-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ This clinical trial is focused on studying a group of lung diseases known as Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). These diseases cause scarring of the lung tissue, which can lead to breathing difficulties. The trial is testing a new treatment called BI 1015550, which is taken as a film-coated tablet. The purpose of the study is to see if BI 1015550 can help improve lung function in people with these conditions.

Participants in the study will be randomly assigned to receive either the BI 1015550 treatment or a placebo, which looks like the treatment but does not contain the active medicine. The study will last for at least 52 weeks, during which time the effects of the treatment on lung function will be closely monitored. The main goal is to see if BI 1015550 can slow down the decline in lung function compared to the placebo.

Throughout the study, participants will have regular check-ups to assess their lung function and overall health. The trial will also look at other important outcomes, such as the time it takes for any worsening of the lung disease, hospitalizations due to breathing problems, or any other serious health events. This research aims to provide valuable information on the safety and effectiveness of BI 1015550 for people living with Progressive Fibrosing Interstitial Lung Diseases.

]]> Study Comparing Cyclophosphamide, Azathioprine, and Tacrolimus for Patients with Antisynthetase Syndrome-Related Interstitial Lung Disease https://clinicaltrials.eu/trial/study-comparing-cyclophosphamide-azathioprine-and-tacrolimus-for-patients-with-antisynthetase-syndrome-related-interstitial-lung-disease/ Wed, 29 Apr 2026 14:59:20 +0000 https://clinicaltrials.eu/trial/study-comparing-cyclophosphamide-azathioprine-and-tacrolimus-for-patients-with-antisynthetase-syndrome-related-interstitial-lung-disease/ This clinical trial is focused on studying a condition known as antisynthetase syndrome-related interstitial lung disease (ASS-ILD). This is a lung disease that can occur in people with antisynthetase syndrome, a rare autoimmune disorder. The study aims to compare the effectiveness of two different treatment approaches for this condition. One group of patients will receive a combination of two medications, Cyclophosphamide and Azathioprine, while the other group will be treated with Tacrolimus. These medications are used to suppress the immune system and reduce inflammation in the lungs.

The purpose of the study is to determine which treatment is more effective in managing ASS-ILD. Participants in the study will be randomly assigned to one of the two treatment groups. The study will last for a period of up to 12 months, during which participants will receive their assigned treatment. Throughout the study, participants will have regular check-ups to monitor their lung function and overall health. The study will also assess the impact of the treatments on participants’ quality of life and any side effects they may experience.

By participating in this study, researchers hope to gather valuable information that could lead to better treatment options for people with ASS-ILD. The study is designed to ensure the safety and well-being of all participants, with regular monitoring and support provided by healthcare professionals. The findings from this study could help improve the management of this challenging condition and provide insights into the most effective treatment strategies.

]]> Study of tezepelumab in patients with progressive pulmonary fibrosis and increased eosinophil levels in blood https://clinicaltrials.eu/trial/study-on-tezepelumab-for-patients-with-progressive-pulmonary-fibrosis-and-eosinophilia/ Wed, 29 Apr 2026 14:59:04 +0000 https://clinicaltrials.eu/trial/study-on-tezepelumab-for-patients-with-progressive-pulmonary-fibrosis-and-eosinophilia/ This clinical trial focuses on progressive pulmonary fibrosis, a serious lung condition where scarring of lung tissue worsens over time, particularly in patients who show increased levels of specific white blood cells called eosinophils. The study will test a medication called Tezepelumab, which is given as an injection under the skin.

The purpose of this research is to determine if Tezepelumab can reduce the number of eosinophils in the blood compared to placebo after 24 weeks of treatment in people with progressive pulmonary fibrosis. The medication will be administered through subcutaneous injection at a dose of 210 mg.

During the study, participants will receive either Tezepelumab or placebo for 24 weeks. After this initial period, some participants may continue receiving treatment in what is called an open-label extension phase. Throughout the study, doctors will monitor various aspects of lung function and overall health through different tests and examinations to evaluate how well the treatment works.

]]> Study of [18F]FAPI-74 PET/CT Imaging in Patients with Connective Tissue Disease at Risk of Lung Fibrosis https://clinicaltrials.eu/trial/study-on-early-detection-of-lung-fibrosis-in-connective-tissue-disease-patients-using-18ffapi-74/ Wed, 29 Apr 2026 14:58:01 +0000 https://clinicaltrials.eu/trial/study-on-early-detection-of-lung-fibrosis-in-connective-tissue-disease-patients-using-18ffapi-74/ This study focuses on patients with connective tissue diseases who are at high risk of developing interstitial lung disease, a condition that causes scarring of the lung tissue. The research uses a special imaging substance called [18F]FAPI-74, which is given through an intravenous injection. This substance helps create detailed images of the lungs using a combination of PET/CT scanning.

The purpose of this research is to compare lung images between patients whose lung condition may worsen over time and those whose condition remains stable. The study will look at how the imaging substance spreads in different parts of the lungs and measure the level of lung tissue changes. The imaging procedure involves lying still while special cameras take pictures of the lungs.

The research also includes collecting blood samples and analyzing tiny particles called extracellular vesicles that can provide information about lung health. Some participants may need to undergo a procedure called bronchoalveolar lavage, where lung fluid is collected to study the lung environment in more detail. The total study duration for each participant includes initial testing and follow-up visits over a 12-month period.

]]> Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-in-adults-with-systemic-sclerosis-associated-interstitial-lung-disease/ Wed, 29 Apr 2026 14:48:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-in-adults-with-systemic-sclerosis-associated-interstitial-lung-disease/ This clinical trial is focused on studying a condition called systemic sclerosis-associated interstitial lung disease (SSc-ILD). This is a disease where the immune system attacks the body, leading to hardening and thickening of the skin and affecting the lungs. The study will test a treatment called belimumab, which is given as an injection under the skin. Belimumab is being compared to a placebo, which looks like the treatment but does not contain the active medicine.

The purpose of the study is to see if belimumab can help reduce the decline in lung function in people with SSc-ILD. Participants will receive either belimumab or a placebo, in addition to their usual treatment, over a period of 52 weeks. The study will monitor changes in lung volume and other health measures to determine the effectiveness and safety of belimumab.

Participants will be asked to self-administer the injections or have a caregiver do it for them. The study aims to provide more information on whether belimumab can be a helpful treatment for people with SSc-ILD, potentially improving their quality of life by slowing down the progression of lung disease.

]]> Study on the Effects of Morphine Sulfate for Relieving Breathlessness and Cough in Patients with Fibrotic Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-morphine-sulfate-for-relieving-breathlessness-and-cough-in-patients-with-fibrotic-interstitial-lung-disease/ Wed, 29 Apr 2026 14:47:55 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-morphine-sulfate-for-relieving-breathlessness-and-cough-in-patients-with-fibrotic-interstitial-lung-disease/ This clinical trial is focused on studying the effects of a medication called morphine sulfate on patients with a lung condition known as Fibrotic Interstitial Lung Disease. This condition involves scarring of the lung tissue, which can lead to symptoms like breathlessness and coughing. The study will use a form of morphine that is released slowly into the body, known as a prolonged-release tablet. The medications being tested include Malfin, Contalgin, and MST CONTINUS, all of which contain morphine sulfate. A placebo will also be used for comparison.

The purpose of the study is to examine how a 4-week treatment with slow-release morphine affects the feeling of breathlessness in patients with fibrotic interstitial lung diseases. Participants will take the medication orally, and the study will compare the effects of morphine to those of a placebo. The study will last for a total of 4 weeks, during which participants will be monitored for changes in their symptoms.

Throughout the study, participants will be asked to report on their symptoms, such as breathlessness and cough, and may undergo tests like a 6-minute walk test to measure their walking distance and oxygen levels. The goal is to see if morphine can help improve the quality of life for people with this lung condition by reducing symptoms like breathlessness and cough.

]]> Study to evaluate oxygen therapy effects on physical activity in patients with fibrotic interstitial lung disease who experience low oxygen levels during exercise https://clinicaltrials.eu/trial/study-on-the-effects-of-oxygen-therapy-for-patients-with-fibrotic-interstitial-lung-disease-and-low-oxygen-levels-during-exercise/ Wed, 29 Apr 2026 14:29:04 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-oxygen-therapy-for-patients-with-fibrotic-interstitial-lung-disease-and-low-oxygen-levels-during-exercise/ This study focuses on patients with fibrotic interstitial lung disease, a condition that causes scarring of the lung tissue and makes breathing difficult. The study specifically looks at patients who experience low oxygen levels (hypoxemia) during physical activity. The treatment being investigated is oxygen therapy, which involves breathing in additional oxygen through specialized equipment.

The purpose of this research is to evaluate how oxygen therapy affects daily physical activity in patients when they exert themselves. The study measures this by tracking the number of steps patients take each day using a special device called an accelerometer. Patients will be monitored for three months to see how oxygen therapy impacts their ability to be physically active.

During the study, some participants will receive oxygen therapy while performing physical activities, while others will serve as a comparison group. The research will look at various aspects of patients’ health, including their breathing difficulties, quality of life, and certain blood markers. The amount of time patients use their oxygen therapy each day will also be tracked.

]]> Study on Long-Term Safety of Inhaled Treprostinil for Patients with Fibrotic Lung Disease https://clinicaltrials.eu/trial/study-on-long-term-safety-of-inhaled-treprostinil-for-patients-with-fibrotic-lung-disease/ Wed, 29 Apr 2026 14:26:32 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-inhaled-treprostinil-for-patients-with-fibrotic-lung-disease/ This clinical trial is focused on studying a condition known as Fibrotic Lung Disease, which involves scarring of the lung tissue that can make breathing difficult. The treatment being tested in this study is called Treprostinil, which is administered as a nebuliser solution. A nebuliser is a device that turns liquid medicine into a mist, making it easier to inhale directly into the lungs. The purpose of this study is to evaluate the long-term safety and tolerability of inhaled Treprostinil in individuals with this lung condition.

Participants in the study will use the Treprostinil nebuliser solution with a device known as the TD-300/A (TD-300), which is part of the Tyvaso Inhalation System. This system includes nebulisers and necessary accessories to help deliver the medication effectively. The study will observe participants over a period to monitor how well they tolerate the treatment and to gather information on any potential side effects.

Throughout the study, researchers will assess various health parameters, such as lung function and overall survival, to understand the effects of continued long-term therapy with Treprostinil. The study aims to provide valuable insights into the treatment’s impact on the progression of Fibrotic Lung Disease and its potential benefits for patients living with this condition.

]]> Study on the Effectiveness and Safety of Rituximab for Patients with Progressive Interstitial Lung Disease with Inflammation https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rituximab-for-patients-with-progressive-interstitial-lung-disease-with-inflammation/ Wed, 29 Apr 2026 14:25:10 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-rituximab-for-patients-with-progressive-interstitial-lung-disease-with-inflammation/ This clinical trial is focused on studying a condition known as Interstitial Lung Disease (ILD), which involves inflammation and scarring of the lung tissue. The study aims to evaluate the effectiveness and safety of a medication called Rituximab in patients with progressive ILD that has an inflammatory component. Rituximab is a medication that targets specific cells in the immune system and is administered through direct intravenous injection. The study will compare the effects of Rituximab to a placebo, which is a substance with no active medication, to see how it impacts lung function over a period of six months.

Participants in the study will receive two infusions of either Rituximab or a placebo. The main goal is to observe changes in lung function, specifically the Forced Vital Capacity (FVC), which measures the amount of air a person can exhale after taking a deep breath. The study will also monitor other health indicators, such as physical activity levels, respiratory symptoms, and any side effects that may occur during the treatment period. The trial is designed to provide valuable information on whether Rituximab can help improve lung function and quality of life for people with this type of lung disease.

Throughout the study, participants will undergo various assessments, including questionnaires about their symptoms and quality of life, as well as tests like the six-minute walk test to measure physical endurance. Additionally, blood tests will be conducted to evaluate changes in certain biological markers related to the immune system. The study will also track any adverse events, particularly infections, to ensure the safety of the participants. The findings from this trial could potentially lead to better treatment options for individuals with progressive Interstitial Lung Disease.

]]> Study on the Use of Hyperpolarized Xenon (129Xe) and Gadobutrol for Imaging in Patients with Progressive Fibrosing Interstitial Lung Diseases https://clinicaltrials.eu/trial/study-on-the-use-of-hyperpolarized-xenon-129xe-and-gadobutrol-for-imaging-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ Wed, 29 Apr 2026 14:24:44 +0000 https://clinicaltrials.eu/trial/study-on-the-use-of-hyperpolarized-xenon-129xe-and-gadobutrol-for-imaging-in-patients-with-progressive-fibrosing-interstitial-lung-diseases/ This clinical trial is focused on studying a group of lung diseases known as Progressive Fibrosing Interstitial Lung Diseases. These diseases cause scarring of the lung tissue, which can make it difficult to breathe. The study will use a special type of imaging called Hyperpolarized 129-Xenon MRI to look at the lungs. This imaging technique involves inhaling a gas called Xenon (129Xe), which helps to create clear pictures of the lungs. The purpose of the study is to see if this imaging can help identify early signs of lung scarring and monitor changes over time.

In addition to the Xenon (129Xe) gas, the study will also use a contrast agent called Gadovist, which is injected into the body to help highlight certain areas during imaging. The study aims to understand how these imaging techniques can be used to track the progression of lung disease and the effects on the heart. Researchers will also evaluate how patients respond to treatments that aim to slow down the scarring process.

Participants in the study will undergo imaging sessions where they will inhale the Xenon (129Xe) gas and receive the Gadovist injection. These sessions will help researchers gather information about lung function and heart health. The study will take place over a period of time, allowing researchers to monitor changes and gather valuable data on the effectiveness of these imaging techniques in managing lung diseases.

]]> Study on the Effects of Wharton’s Jelly Mesenchymal Stem Cells, Pirfenidone, and Nintedanib for Patients with Fibrotic Interstitial Lung Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-whartons-jelly-mesenchymal-stem-cells-pirfenidone-and-nintedanib-for-patients-with-fibrotic-interstitial-lung-disease/ Wed, 29 Apr 2026 14:22:31 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-whartons-jelly-mesenchymal-stem-cells-pirfenidone-and-nintedanib-for-patients-with-fibrotic-interstitial-lung-disease/ This clinical trial is focused on studying the effects of a new treatment for fibrotic interstitial lung diseases, which include conditions like idiopathic pulmonary fibrosis and lung fibrosis that can occur after recovering from COVID-19. The treatment being tested involves the use of allogeneic mesenchymal stem cells derived from Wharton’s jelly, which are special cells that may help repair lung tissue. These stem cells are given as an injection. The study also involves other medications, such as Esbriet (pirfenidone) and Ofev (nintedanib), which are taken orally as tablets or capsules.

The purpose of the study is to evaluate the safety and effectiveness of these treatments in managing fibrotic lung diseases. Participants in the study will receive either the stem cell treatment, one of the medications, or a placebo. The study will monitor the number and severity of any side effects, changes in lung function, quality of life, and overall survival over the course of the study.

Throughout the study, participants will undergo regular check-ups to assess their lung function and overall health. The study aims to determine if the new treatment can slow down the progression of lung disease and improve the quality of life for those affected. The trial is expected to continue until March 2025, with ongoing assessments to gather comprehensive data on the treatment’s impact.

]]>